PR Newswire01.25.19
Functional Neuromodulation Ltd. (FNM), a medical device company focused on bringing to market DBS-f, an implantable deep brain stimulation (DBS) therapy targeting the fornix for mild Alzheimer's disease patients, announces that Todd Langevin will succeed Vincent Owens as CEO with effect from January 25, 2019. Owens will remain deeply involved in the company as Executive Chairman.
Langevin most recently served as president and COO of FNM since its formation in 2011. Prior to joining FNM, Langevin held senior leadership roles at medical device companies including CVRx and Medtronic. His prior roles during a 20-year career at Medtronic included Vice President & General Manager of Medtronic's DBS Movement Disorders Business and an earlier role as European Business Director, Neuromodulation.
Owens, Executive Chairman of FNM commented: "Todd has been instrumental in leading the company through the ADvance I study, CE mark approval, and IDE approval of the ADvance II pivotal study of DBS-f. FNM's investors, employees and I have great confidence in Todd's leadership and we look forward to beginning enrollment in ADvance II."
Langevin most recently served as president and COO of FNM since its formation in 2011. Prior to joining FNM, Langevin held senior leadership roles at medical device companies including CVRx and Medtronic. His prior roles during a 20-year career at Medtronic included Vice President & General Manager of Medtronic's DBS Movement Disorders Business and an earlier role as European Business Director, Neuromodulation.
Owens, Executive Chairman of FNM commented: "Todd has been instrumental in leading the company through the ADvance I study, CE mark approval, and IDE approval of the ADvance II pivotal study of DBS-f. FNM's investors, employees and I have great confidence in Todd's leadership and we look forward to beginning enrollment in ADvance II."